Oculis Holding AG
OCS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001953530
No open-market purchases or sales by Oculis Holding AG insiders were filed in the last 90 days; 59 institutions reported holding it in 13F filings for Q2 2026, worth $322.0M in total; no superinvestor holds it.
Other share classesOCSAW
Q1 2023 vs. Q4 2022
How the institutions holding Oculis Holding AG changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 0 | 7 | +7 |
| Shares | 0 | 3.12M | +3.12M |
| Value | $0 | $23.2M | +$23.2M |
New holders (7)
Institutions that held Oculis Holding AG at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 2,381,196 | $17.7M | 7.28% |
| Nan Fung Group Holdings Ltd | 651,100 | $4.84M | 3.29% |
| Compagnie Lombard Odier SCmA | 65,000 | $471.9K | 0.01% |
| HRT Financial LP | 24,609 | $178.0K | 0.00% |
| UBS Group AG | 1,212 | $9.01K | 0.00% |
| Elequin Capital LP | 300 | $2.23K | 0.00% |
| DuPont Capital Management Corp | 4 | $29 | 0.00% |
Sold out (0)
Institutions that held Oculis Holding AG at the end of Q4 2022 and filed for Q1 2023 without it.
None.